| Abstrakt: |
I SP 1 sp Neuroscience Research Australia, Randwick, NSW 2031, Australia, 2School of Medical Sciences, University of New South Wales, Kensington, NSW 2052, Australia, SP 3 sp Continence Clinic, MS Limited, Sydney, Australia, SP 4 sp Australian Catholic University, Sydney, Australia, SP 5 sp Prince of Wales Clinical School, University of New South Wales Medicine, University of New South Wales, Kensington, NSW 2052, Australia i B Background: b The symptoms that have the largest impact on quality of life (QoL) in people with multiple sclerosis (MS) might be different by MS phenotype (relapsing-remitting MS, RRMS; secondary progressive MS, SPMS; primary progressive MS, PPMS). B Objectives: b Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-specific disease-modifying therapy (DMT) prescription data and estimate the change in prevalence from 2010. I SP 1 sp Neuroscience Research Australia, Randwick, NSW 2031, Australia; SP 2 sp School of Medical Sciences, University of New South Wales, Kensington, NSW 2052, Australia; SP 3 sp Continence Clinic, MS Limited, Sydney, Australia; SP 4 sp Australian Catholic University, Sydney, Australia; SP 5 sp Prince of Wales Clinical School, University of New South Wales Medicine, University of New South Wales, Kensington, NSW 2052, Australia i B Background: b The health-related quality of life (HRQoL) of people with Multiple Sclerosis (MS) is affected by the presence of comorbidities but only few studies have examined the impact of common comorbidities on HRQoL in people with MS. [Extracted from the article] |
